Dr. Steven B. Ketchum is the president of research and development and senior vice president of Amarin Corporation, an Irish biopharmaceutical company.
Ketchum has nearly 30 years of experience in clinical regulatory strategy and late-stage product development from leading the filings of many successful new drug applications (NDAs). Since joining Amarin in 2012, Ketchum has led the company’s drug discovery, preclinical and clinical development program, and regulatory and medical affairs activities. He was also elected to Amarin’s board of directors in 2012.
Prior to his role at Amarin, Ketchum was the senior vice president of research and development at Sunesis Pharmaceuticals where he guided all areas of pharmaceutical research, clinical development and strategy, and regulatory affairs.
The pharmaceutical leader also has held the titles of senior vice president of research and development and medical affairs and senior vice president of operations and regulatory affairs for Reliant Pharmaceuticals and IntraBiotics Pharmaceuticals, Inc., respectively.
Ketchum began his career by gaining extensive experience in regulatory affairs with ALZA, a pharmaceutical and medical supplies company where he worked for eight years ending in 2004.
Ketchum earned his Ph.D. in pharmacology at the University College London in 1990 and his B.S. in biological sciences at Stanford University.
What is Steven B. Ketchum's net worth?
The estimated net worth of Steven B. Ketchum is at least $409.86 thousand as of December 12th, 2023. Mr. Ketchum owns 28,305 shares of Amarin stock worth more than $409,856 as of April 10th. This net worth evaluation does not reflect any other assets that Mr. Ketchum may own. Learn More about Steven B. Ketchum's net worth.
How do I contact Steven B. Ketchum?
Has Steven B. Ketchum been buying or selling shares of Amarin?
Steven B. Ketchum has not been actively trading shares of Amarin within the last three months. Most recently, Steven B. Ketchum sold 1,706 shares of the business's stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $15.80, for a transaction totalling $26,954.80. Following the completion of the sale, the insider now directly owns 28,305 shares of the company's stock, valued at $447,219. Learn More on Steven B. Ketchum's trading history.
Who are Amarin's active insiders?
